← SGLT2 inhibitors × kidney outcomes

TrialJournal of the American Society of Nephrology : JASN2020

Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A

Megumi Oshima et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 4,401 people · 2020

Randomised comparison

Raised kidney outcomes

2.7×2.4× to 3.1×

Bigger than 9 in 10 on the map

As reported

OR 2.69, 95% CI 2.35–3.07

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower kidney outcomes

−29%−33% to −24%

Bigger than 6 in 10 on the map

As reported

HR 0.71, 95% CI 0.67–0.76

Two numbers in the abstract

the abstract, start to end

… a 30% reduction in UACR (odds ratio, 2.69; 95% CI, 2.35 to 3.07).

… kidney outcome (hazard ratio [HR], 0.71; 95% CI, 0.67 to 0.76; …

← favours treatmentfavours comparator →
could be chance
Kidney outcomes
OR 2.692.35–3.07
Kidney outcomes
HR 0.710.67–0.76
SGLT2 inhibitorsKidney outcomes

SGLT2 inhibitors × kidney outcomeshelps?settled

unlikelylikely
0.890.88 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 6

90 papers cite itlatest 60 shown

2020
…
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 32998938